Trial Profile
Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2021
Price :
$35
*
At a glance
- Drugs Dilpacimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Sponsors AbbVie
- 20 Jan 2021 Status changed from completed to discontinued.
- 06 Aug 2020 This trial has been discontinued in Belgium, according to European Clinical Trials Database record.
- 11 Feb 2020 Status changed from active, no longer recruiting to completed.